A High-Throughput, Multi-Index Isothermal Amplification Platform for Rapid Detection of 19 Types of Common Respiratory Viruses Including SARS-CoV-2
Wanli Xing,
Yingying Liu,
Huili Wang,
Shanglin Li,
Yongping Lin,
Lei Chen,
Yan Zhao,
Shuang Chao,
Xiaolan Huang,
Shaolin Ge,
Tao Deng,
Tian Zhao,
Baolian Li,
Hanbo Wang,
Lei Wang,
Yunpeng Song,
Ronghua Jin,
Jianxing He,
Xiuying Zhao,
Peng Liu,
Weimin Li,
Jing Cheng
Affiliations
Wanli Xing
Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing 100084, China; National Engineering Research Center for Beijing Biochip Technology, Beijing 102206, China; CapitalBio Technology, Beijing 101111, China
Yingying Liu
National Engineering Research Center for Beijing Biochip Technology, Beijing 102206, China; CapitalBio Corporation, Beijing 102206, China
Huili Wang
Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China
Shanglin Li
Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing 100084, China
Yongping Lin
Department of Laboratory Medicine, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
Lei Chen
Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, China
Yan Zhao
Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
Shuang Chao
Department of Pediatrics, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
Xiaolan Huang
Experiment Center, Capital Institute of Pediatrics, Beijing 100020, China
Shaolin Ge
National Engineering Research Center for Beijing Biochip Technology, Beijing 102206, China; CapitalBio Corporation, Beijing 102206, China
Tao Deng
CapitalBio Technology, Beijing 101111, China
Tian Zhao
National Engineering Research Center for Beijing Biochip Technology, Beijing 102206, China; CapitalBio Corporation, Beijing 102206, China
Baolian Li
National Engineering Research Center for Beijing Biochip Technology, Beijing 102206, China; CapitalBio Corporation, Beijing 102206, China
Hanbo Wang
National Engineering Research Center for Beijing Biochip Technology, Beijing 102206, China; CapitalBio Corporation, Beijing 102206, China
Lei Wang
National Engineering Research Center for Beijing Biochip Technology, Beijing 102206, China; CapitalBio Corporation, Beijing 102206, China
Yunpeng Song
CapitalBio Technology, Beijing 101111, China
Ronghua Jin
President’s Office, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
Jianxing He
Department of Cardiothoracic Surgery, State Key Laboratory of Respiratory Disease, China Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
Xiuying Zhao
Department of Clinical Laboratory, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
Peng Liu
Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing 100084, China; Corresponding authors.
Weimin Li
Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China; Corresponding authors.
Jing Cheng
Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing 100084, China; National Engineering Research Center for Beijing Biochip Technology, Beijing 102206, China; CapitalBio Corporation, Beijing 102206, China; Corresponding authors.
Fast and accurate diagnosis and the immediate isolation of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are regarded as the most effective measures to restrain the coronavirus disease 2019 (COVID-19) pandemic. Here, we present a high-throughput, multi-index nucleic acid isothermal amplification analyzer (RTisochip™-W) employing a centrifugal microfluidic chip to detect 19 common respiratory viruses, including SARS-CoV-2, from 16 samples in a single run within 90 min. The limits of detection of all the viruses analyzed by the RTisochip™-W system were equal to or less than 50 copies·μL−1, which is comparable to those of conventional reverse transcription polymerase chain reaction. We also demonstrate that the RTisochip™-W system possesses the advantages of good repeatability, strong robustness, and high specificity. Finally, we analyzed 201 cases of preclinical samples, 14 cases of COVID-19-positive samples, 25 cases of clinically diagnosed samples, and 614 cases of clinical samples from patients or suspected patients with respiratory tract infections using the RTisochip™-W system. The test results matched the referenced results well and reflected the epidemic characteristics of the respiratory infectious diseases. The coincidence rate of the RTisochip™-W with the referenced kits was 98.15% for the detection of SARS-CoV-2. Based on these extensive trials, we believe that the RTisochip™-W system provides a powerful platform for fighting the COVID-19 pandemic.
